Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1993
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A new market outlook covering 2026-2030 projects continued growth in ADME toxicology testing demand, driven by expansion of the global pharmaceutical industry. - North America was the largest regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region through the forecast period. - European pharmaceutical production reached EUR 390.0 billion ($422.8 billion) in 2023, up from EUR 363.3 billion ($393.9 billion) in 2022, according to EFPIA. - Evotec SE launched the Cyprotex e-Store in October 2023, an e-commerce platform providing online access to its ADME-Tox service portfolio.
- Just – Evotec Biologics initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses, under the U.S. Department of War's Accelerated Antibodies Program. - JST-018 is being developed as a prophylactic therapy to protect warfighters at elevated risk of exposure to biological threats, including the variola virus that causes smallpox and the mpox virus. - The program advanced from antibody sequence selection through cGMP manufacture at the J.POD facility in Redmond, Washington, using continuous bioprocessing rather than batch manufacturing. - The orthopoxvirus program is the second under the Accelerated Antibodies Program, with the two contracts carrying a combined potential value of up to $123.9 million.
- Evotec SE and Plectonic Biotech announced a research collaboration combining Evotec's BiTco CD2 costimulatory bispecific platform with Plectonic's logic-gated LOGIBODY® DNA-protein immunotherapy technology. - The partnership aims to address key challenges that have limited T cell engager therapies in solid tumors, which represent approximately 90 percent of all cancers. - The collaboration will generate preclinical proof-of-concept data to evaluate whether combining selective tumor recognition with enhanced T-cell activation improves precision and potency. - Plectonic's LOGIBODY® requires simultaneous binding to a predefined multi-antigen tumor signature, while Evotec's BiTco provides a non-blocking CD2 costimulatory signal to enhance T cell activity and delay exhaustion.
- Evotec SE and Odyssey Therapeutics have entered a strategic R&D collaboration to discover new small molecule treatments for autoimmune and inflammatory diseases. - Odyssey will leverage Evotec's AI-enabled discovery platform, advanced screening capabilities, and proprietary compound libraries to identify validated hit series across multiple high-value targets. - The collaboration combines high-throughput experimentation with machine learning-driven analysis to accelerate early-stage research and advance promising therapeutic programs. - Evotec is eligible to receive milestone payments based on successful delivery of validated hit series for each target, though detailed financial terms were not disclosed.
- Evotec's multi-omics study profiled plasma from 76 individuals across SLE, MS, Crohn's disease, and ulcerative colitis using metabolomics, lipidomics, and proteomics to uncover disease-specific molecular signatures. - Systemic lupus erythematosus exhibited the most distinct molecular profile, reflecting systemic metabolic stress, while MS patients clustered closer to healthy volunteers despite active underlying pathology. - Machine learning models achieved F1 scores from approximately 0.84 to nearly 1, identifying compact biomarker panels that distinguish each disease from healthy controls. - Of the top 60 candidate biomarkers, 33 represented potentially novel candidates, demonstrating the value of integrating multiple molecular layers for precision medicine.
- Nearly 90% of drug candidates fail in human trials due to efficacy or toxicity gaps, driving adoption of New Approach Methodologies (NAMs) including humanized mouse models, organ-on-a-chip, and AI. - Human liver-on-a-chip models achieved over 87% sensitivity and 100% specificity in predicting drug-induced liver injury, outperforming traditional animal safety screens. - AI algorithms can now screen billions of compounds in two days, but experts caution that computational speed does not guarantee clinical efficacy, citing Exscientia's failed AI-designed candidate. - The AI-accelerated nonclinical drug testing market is valued at USD 1,090.7 million in 2026 and projected to reach USD 4,489.9 million by 2036 at a 15.2% CAGR.
- Evotec, a global drug discovery and development company, has selected Navan to manage its complete corporate travel and expense program across its top global markets. - The rollout spans Germany, the UK, U.S., Italy, and France, replacing a patchwork of disparate tools and manual offline processes with one unified platform. - The transition aims to enhance operational excellence by automating reconciliation directly from the point of swipe and reducing manual expense reporting. - Navan's AI-powered platform will provide Evotec with real-time visibility and control over global travel and expense activities, supporting teams in focusing on core R&D work.
- Technology transfer is a pivotal milestone in cell therapy development, bridging laboratory-scale processes with GMP manufacturing for first-in-human clinical trials. - A new whitepaper from Evotec outlines key challenges including research-grade raw materials, equipment variability, and complex analytical assay implementation at receiving units. - Successful tech transfer safeguards product quality, ensures regulatory compliance, and forms the basis for process validation and ongoing continual improvement per ICH Q10 guidelines. - Poor execution of tech transfer can compromise patient safety and product quality, making strategic planning essential for small biotech companies with limited resources.
- The Alport syndrome market across the 7MM was valued at USD 27 million in 2025, with the United States accounting for approximately 88% of the total market share. - No therapies are currently approved specifically for Alport syndrome; standard care relies on ACE inhibitors, ARBs, and kidney transplantation for end-stage disease. - ENYO Pharma's vonafexor demonstrated positive Phase II ALPESTRIA-1 results in January 2026, showing slowed kidney function decline, with a Phase III trial planned for 2H 2026. - The pipeline includes diverse mechanisms such as ELX-02 for nonsense mutations, setanaxib (NOX1/4 inhibitor), and BAY3401016 (anti-Sema3A monoclonal antibody), with total prevalent cases estimated at ~203,800 in the 7MM in 2025.
- Symeres and Axxam have appointed Russell Thomas as Chief Scientific Officer to lead their joint integrated drug discovery platform spanning target assessment through IND-ready packages. - The appointment deepens the strategic collaboration between the Dutch CRDMO and Italian biology-driven discovery services provider in response to growing demand for end-to-end R&D partners. - Thomas brings extensive experience from leadership roles at GSK, Evotec, Siena Biotech, Proteros, and prior tenures at both Symeres and Axxam. - Both CEOs emphasized that Thomas's dual-company experience uniquely positions him to connect scientific capabilities, teams, and platforms across the two organizations.
